These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 31066991)

  • 1. Nebivolol in the treatment of arterial hypertension.
    Olawi N; Krüger M; Grimm D; Infanger M; Wehland M
    Basic Clin Pharmacol Toxicol; 2019 Sep; 125(3):189-201. PubMed ID: 31066991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nebivolol: impact on cardiac and endothelial function and clinical utility.
    Toblli JE; DiGennaro F; Giani JF; Dominici FP
    Vasc Health Risk Manag; 2012; 8():151-60. PubMed ID: 22454559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics.
    Agabiti Rosei E; Rizzoni D
    Drugs; 2007; 67(8):1097-107. PubMed ID: 17521213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of obstructive sleep apnea on the response to hypertension therapy.
    Ziegler MG; Milic M; Lu X; Gharaibeh M; Elayan H
    Clin Exp Hypertens; 2017; 39(5):409-415. PubMed ID: 28557555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of nebivolol in the management of hypertensive patients: from pharmacological profile to treatment guidelines.
    Ferri C
    Future Cardiol; 2021 Nov; 17(8):1421-1433. PubMed ID: 34060323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacodynamics of nebivolol: new evidence of nitric oxide-mediated vasodilating activity and peculiar haemodynamic properties in hypertensive patients.
    Zanchetti A
    Blood Press Suppl; 2004 Oct; 1():17-32. PubMed ID: 15587108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nebivolol: endothelium-mediated vasodilating effect.
    Ritter JM
    J Cardiovasc Pharmacol; 2001 Dec; 38 Suppl 3():S13-6. PubMed ID: 11811387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nebivolol: an endothelium-friendly selective β1-adrenoceptor blocker.
    Gao Y; Vanhoutte PM
    J Cardiovasc Pharmacol; 2012 Jan; 59(1):16-21. PubMed ID: 21283024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Third-generation beta-adrenoceptor antagonists in the treatment of hypertension and heart failure.
    Fisker FY; Grimm D; Wehland M
    Basic Clin Pharmacol Toxicol; 2015 Jul; 117(1):5-14. PubMed ID: 25732141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological mechanisms of clinically favorable properties of a selective beta1-adrenoceptor antagonist, nebivolol.
    Kuroedov A; Cosentino F; Lüscher TF
    Cardiovasc Drug Rev; 2004; 22(3):155-68. PubMed ID: 15492765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential Metabolic Effects of Beta-Blockers: an Updated Systematic Review of Nebivolol.
    Marketou M; Gupta Y; Jain S; Vardas P
    Curr Hypertens Rep; 2017 Mar; 19(3):22. PubMed ID: 28283926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nebivolol for improving endothelial dysfunction, pulmonary vascular remodeling, and right heart function in pulmonary hypertension.
    Perros F; Ranchoux B; Izikki M; Bentebbal S; Happé C; Antigny F; Jourdon P; Dorfmüller P; Lecerf F; Fadel E; Simonneau G; Humbert M; Bogaard HJ; Eddahibi S
    J Am Coll Cardiol; 2015 Feb; 65(7):668-80. PubMed ID: 25677428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nitric oxide, erectile dysfunction and beta-blocker treatment (MR NOED study): benefit of nebivolol versus metoprolol in hypertensive men.
    Brixius K; Middeke M; Lichtenthal A; Jahn E; Schwinger RH
    Clin Exp Pharmacol Physiol; 2007 Apr; 34(4):327-31. PubMed ID: 17324145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nebivolol and valsartan as a fixed-dose combination for the treatment of hypertension.
    Sander GE; Giles TD
    Expert Opin Pharmacother; 2015 Apr; 16(5):763-70. PubMed ID: 25747524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Review of Nebivolol Pharmacology and Clinical Evidence.
    Fongemie J; Felix-Getzik E
    Drugs; 2015 Aug; 75(12):1349-71. PubMed ID: 26177892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of nebivolol or irbesartan in combination with hydrochlorothiazide on vascular functions in newly-diagnosed hypertensive patients: the NINFE (Nebivololo, Irbesartan Nella Funzione Endoteliale) study.
    Vitale C; Marazzi G; Iellamo F; Spoletini I; Dall'Armi V; Fini M; Volterrani M
    Int J Cardiol; 2012 Mar; 155(2):279-84. PubMed ID: 22078979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nebivolol: a third-generation beta-blocker for hypertension.
    Cheng JW
    Clin Ther; 2009 Mar; 31(3):447-62. PubMed ID: 19393838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective effects of nebivolol from oxidative stress to prevent hypertension-related target organ damage.
    Coats A; Jain S
    J Hum Hypertens; 2017 Jun; 31(6):376-381. PubMed ID: 28252041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nebivolol: third-generation beta-blockade.
    de Boer RA; Voors AA; van Veldhuisen DJ
    Expert Opin Pharmacother; 2007 Jul; 8(10):1539-50. PubMed ID: 17661735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of nebivolol versus other antihypertensive drugs on the endothelial dysfunction in patients with essential hypertension.
    Li B; Zhang Q; Zhang H; Wang C; Xiu R
    Biosci Rep; 2020 May; 40(5):. PubMed ID: 32342981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.